Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7

specific

Stage III includes: (T3, N0, M0); (T1, N1, M0); (T2, N1, M0); (T3, N1, M0). T1: Supraglottis: Tumor limited to one subsite of supraglottis with normal vocal cord mobility. Glottis: Tumor limited to the vocal cord(s) (may involve anterior or posterior commissure) with normal mobility. Subglottis: Tumor limited to the subglottis. T2: Supraglottis: Tumor invades mucosa of more than one adjacent subsite of supraglottis or glottis or region outside the supraglottis (e.g., mucosa of base of tongue,

65

Centers

72

Active Trials

Cancer Funding

Top Centers for Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7(65)

Ranked by research excellence score (trials · grants · publications). Methodology →

#CenterScore
1
NCI Comprehensive
High-Volume Research Center
70.8
270.8
3
NCI Comprehensive
High-Volume Research Center
70.8
4
NCI Comprehensive
High-Volume Research Center
70.8
5
NCI Comprehensive
High-Volume Research Center
70.8
6
NCI Comprehensive
High-Volume Research Center
70.8
7
Rutgers Cancer InstituteNew Brunswick, NJ
NCI Comprehensive
High-Volume Research Center
70.8
8
NCI Comprehensive
Active Research Program
48.3
9
NCI Comprehensive
Active Research Program
48.3
10
NCI Comprehensive
Active Research Program
48.3
11
NCI Comprehensive
Active Research Program
48.3
12
NCI Comprehensive
Active Research Program
48.3
13
NCI Comprehensive
Active Research Program
48.3
14
NCI Comprehensive
Active Research Program
48.3
15
NCI Comprehensive
Active Research Program
48.3
16
NCI Comprehensive
Active Research Program
48.3
17
NCI Comprehensive
Active Research Program
48.3
18
NCI Comprehensive
Active Research Program
48.3
19
NCI Comprehensive
Active Research Program
48.3
20
NCI Comprehensive
Active Research Program
48.3
21
NCI Comprehensive
Active Research Program
48.3
22
NCI Comprehensive
Active Research Program
48.3
23
NCI Comprehensive
Active Research Program
48.3
24
NCI Comprehensive
Active Research Program
48.3
25
NCI Comprehensive
Active Research Program
48.3
26
NCI Comprehensive
Active Research Program
48.3
27
NCI Comprehensive
Active Research Program
48.3
28
NCI Comprehensive
Active Research Program
48.3
29
NCI Comprehensive
Active Research Program
48.3
30
NCI Comprehensive
Active Research Program
48.3
31
NCI Comprehensive
Active Research Program
48.3
32
NCI Clinical
Active Research Program
48.3
33
NCI Comprehensive
Active Research Program
48.3
34
Active Research Program
48.3
35
Cedars-Sinai CancerLos Angeles, CA
Active Research Program
48.3
36
NCI Comprehensive
Active Research Program
48.3
37
NCI Clinical
Active Research Program
48.3
38
Active Research Program
48.3
39
NCI Comprehensive
Active Research Program
48.3
40
NCI Comprehensive
Active Research Program
48.3
41
NCI Clinical
Active Research Program
48.3
42
NCI Comprehensive
Active Research Program
48.3
43
NCI Comprehensive
Active Research Program
48.3
44
Active Research Program
48.3
45
NCI Clinical
Active Research Program
48.3
46
NCI Comprehensive
Active Research Program
48.3
47
Active Research Program
48.3
48
Fox Chase Cancer CenterPhiladelphia, PA
NCI Comprehensive
Active Research Program
48.3
49
Active Research Program
48.3
50
NCI Comprehensive
Active Research Program
48.3
5148.3
52
Active Research Program
48.3
53
Active Research Program
48.3
54
Active Research Program
48.3
55
Active Research Program
48.3
56
Active Research Program
48.3
57
Active Research Program
48.3
58
Active Research Program
48.3
59
Active Research Program
48.3
60
Active Research Program
48.3
61
Active Research Program
48.3
62
Active Research Program
48.3
63
Active Research Program
48.3
64
Active Research Program
48.3
65
Active Research Program
48.3

Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →